ahlam1399
07-18-2016, 06:23 AM
Samsung Bioepis seeks Europe approval for its Humira copy
SEOUL (Reuters) - Biosimilars maker Samsung Bioepis, part of South Korea's top family-run conglomerate Samsung Group [SAGR.UL], said on Monday it is seeking regulatory approval in Europe to sell its copy of AbbVie Inc's rheumatoid arthritis drug Humira.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=yz6dRWxZobk:8R97a0247uI:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=yz6dRWxZobk:8R97a0247uI:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=yz6dRWxZobk:8R97a0247uI:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=yz6dRWxZobk:8R97a0247uI:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=yz6dRWxZobk:8R97a0247uI:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/yz6dRWxZobk
SEOUL (Reuters) - Biosimilars maker Samsung Bioepis, part of South Korea's top family-run conglomerate Samsung Group [SAGR.UL], said on Monday it is seeking regulatory approval in Europe to sell its copy of AbbVie Inc's rheumatoid arthritis drug Humira.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=yz6dRWxZobk:8R97a0247uI:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=yz6dRWxZobk:8R97a0247uI:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=yz6dRWxZobk:8R97a0247uI:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=yz6dRWxZobk:8R97a0247uI:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=yz6dRWxZobk:8R97a0247uI:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/yz6dRWxZobk